other material
confidence high
sentiment positive
materiality 0.85
Zentalis reports azenosertib ORR 34.9% in Cyclin E1+ PROC; FDA aligned on DENALI Part 2 for accelerated approval path
Zentalis Pharmaceuticals, Inc.
- DENALI Part 1b in Cyclin E1+ PROC achieved 34.9% ORR (response-evaluable n=43) and ~5.5 months median DOR; ITT ORR 31.3%.
- FDA aligned on seamless DENALI Part 2 design; enrollment to begin 1H 2025 with topline data by year-end 2026; potential accelerated approval.
- MAMMOTH monotherapy in Cyclin E1+ patients at 400mg QD 5:2 showed 31.3% ORR (n=16); safety profile well-characterized with low discontinuation rate.
- Company discontinues ZN-c3-016 (BRAF CRC expansion) due to resource prioritization; no further development of niraparib combination.
- Corporate restructuring extended cash runway into late 2027, beyond expected DENALI Part 2 data readout.